Compare Intuitive Surgical, Inc. (ISRG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Smith & Nephew plc — how do they compare? Intuitive Surgical, Inc. trades at $423.96 (market cap $146.76B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Intuitive Surgical, Inc. is far larger — about 13.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Smith & Nephew plc for 121 Days on average.
| ISRG | SNN | |
|---|---|---|
Market Cap | $146.76B | $11.10B |
Volume | 2,529,814 | 1,051,703 |
Sector | Health | Health |
52-Week High | $592.85 | $37.17 |
52-Week Low | $332.02 | $26.42 |
Typical Hold Time | 84 Days | 121 Days |
Enterprise Value | $141.54B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $415.41, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.80, and has shown consistent revenue growth, reaching $10.06B in 2025. Analyst consensus is strongly bullish with a $480.78 price target, though the stock faces headwinds from slower procedure growth in some markets.
The outlook for ISRG remains positive due to its dominant position in robotic surgery, expanding international presence, and high recurring revenue. Key risks include competitive pressures, regulatory hurdles, and economic sensitivity affecting procedure volumes. With solid fundamentals and analyst support, the stock offers growth potential, but investors should monitor execution against these risks.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
